Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tivozanib hydrochloride

(ty-VOH-zuh-nib HY-droh-KLOR-ide)
A drug used to treat adults with advanced renal cell carcinoma (a type of kidney cancer). It is used in patients whose cancer has relapsed (come back) or has not gotten better after treatment with at least two other types of systemic therapy. It is also being studied in the treatment of other types of cancer. Tivozanib hydrochloride blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Tivozanib hydrochloride is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called Fotivda.
More Information
Search NCI's Dictionary of Cancer Terms